Team approach allows Amgen to complete new biomanufacturing plant in 2020

CLOSE EYE: From left, associate manufacturer Adeline Lamothe, manufacturing process technician contract worker Austin White and associate manufacturer David Folco check the single-use bioreactors, which are used to control the conditions for generating protein cells at Amgen Rhode Island in West Greenwich. / COURTESY AMGEN INC.
CLOSE EYE: From left, associate manufacturer Adeline Lamothe, manufacturing process technician contract worker Austin White and associate manufacturer David Folco check the single-use bioreactors, which are used to control the conditions for generating protein cells at Amgen Rhode Island in West Greenwich. / COURTESY AMGEN INC.
PBN Manufacturing Awards 2021 Overall Excellence at an Enterprise Manufacturer: Amgen Rhode Island Amgen Inc. develops medications for oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience conditions for which treatment options are often limited. The company has invested more than $1.5 billion in its 75-acre Amgen Rhode Island complex in West Greenwich, including just…

You must be a subscriber to read this content. To keep reading and receive unlimited access subscribe today for only $1.
Subscribe Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display